Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M.

Oncogene. 2009 Aug 6;28(31):2773-83. doi: 10.1038/onc.2009.135. Epub 2009 Jun 15.

PMID:
19525976
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling.

Britson JS, Barton F, Balko JM, Black EP.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):849-54. doi: 10.1016/j.bbrc.2009.10.061. Epub 2009 Oct 20.

PMID:
19836351
[PubMed - indexed for MEDLINE]
3.

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.

Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M, Hirohashi S.

Cancer Sci. 2007 Jul;98(7):985-91. Epub 2007 Apr 23.

PMID:
17459062
[PubMed - indexed for MEDLINE]
4.

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):710-7.

PMID:
16467080
[PubMed - indexed for MEDLINE]
Free Article
5.

Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features.

Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, Matsuno Y, Tsuchiya R, Kanai Y, Kondo T, Imoto I, Inazawa J, Hirohashi S.

Clin Cancer Res. 2005 Sep 1;11(17):6177-85.

PMID:
16144918
[PubMed - indexed for MEDLINE]
Free Article
7.

Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers.

Lam DC, Girard L, Suen WS, Chung LP, Tin VP, Lam WK, Minna JD, Wong MP.

J Thorac Oncol. 2006 Nov;1(9):932-42.

PMID:
17409975
[PubMed - indexed for MEDLINE]
8.

TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma.

Pallier K, Cessot A, Côté JF, Just PA, Cazes A, Fabre E, Danel C, Riquet M, Devouassoux-Shisheboran M, Ansieau S, Puisieux A, Laurent-Puig P, Blons H.

PLoS One. 2012;7(1):e29954. doi: 10.1371/journal.pone.0029954. Epub 2012 Jan 17.

PMID:
22272264
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
[PubMed - indexed for MEDLINE]
10.

Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.

Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, Chen CY, Yu CJ, Shih JY, Chang YL, Cheng CL, Hsu CP, Hsia JY, Lin CY, Wu G, Liu CH, Wang CD, Yang KC, Chen YW, Lai YL, Hsu CC, Lin TC, Yang TY, Chen KC, Hsu KH, Chen JJ, Chang GC, Li KC, Yang PC.

J Clin Oncol. 2011 Sep 1;29(25):3435-42. doi: 10.1200/JCO.2011.35.3979. Epub 2011 Aug 1.

PMID:
21810691
[PubMed - indexed for MEDLINE]
11.

CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer.

Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, Thu K, Rios JJ, Yang C, Marconett CN, Selamat SA, Laird-Offringa IA, Taguchi A, Hanash S, Shames D, Ma X, Zhang MQ, Lam WL, Gazdar A.

J Thorac Oncol. 2013 Nov;8(11):1378-88. doi: 10.1097/JTO.0b013e3182a46c0c.

PMID:
24077454
[PubMed - indexed for MEDLINE]
12.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

PMID:
19584155
[PubMed - indexed for MEDLINE]
Free Article
13.

Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.

Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR.

Cancer Res. 2009 Nov 1;69(21):8341-8. doi: 10.1158/0008-5472.CAN-09-2477. Epub 2009 Oct 13.

PMID:
19826035
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.

Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, Shen L, Ji H, Chen H.

J Thorac Oncol. 2012 Jan;7(1):85-9. doi: 10.1097/JTO.0b013e318234f0a2.

PMID:
22071781
[PubMed - indexed for MEDLINE]
15.

Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma.

Li C, Sun Y, Fang Z, Han X, Fang R, Zhang Y, Pan Y, Zhang W, Ren Y, Ji H, Chen H.

J Thorac Oncol. 2011 Jun;6(6):1016-21. doi: 10.1097/JTO.0b013e318215a4f2.

PMID:
21532505
[PubMed - indexed for MEDLINE]
16.

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.

Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH.

Lung Cancer. 2008 Jan;59(1):111-8. Epub 2007 Sep 29.

PMID:
17904685
[PubMed - indexed for MEDLINE]
17.

Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.

Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M.

J Pathol. 2008 Feb;214(3):347-56.

PMID:
17992665
[PubMed - indexed for MEDLINE]
18.

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.

Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P.

Cancer Res. 2007 Jun 15;67(12):5667-72.

PMID:
17575133
[PubMed - indexed for MEDLINE]
Free Article
19.

Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba II.

Cancer Prev Res (Phila). 2008 Aug;1(3):192-200. doi: 10.1158/1940-6207.CAPR-08-0032.

PMID:
19138956
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF.

J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

PMID:
15741570
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk